SpyGlass Pharma SGP
Medical - Instruments & Supplies, Healthcare
$33.64
+4.34%
- Market cap
- $1.1B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| R&D | $6.1M | $7.3M | $8.5M | $10.9M |
| SG&A | $1.4M | $2M | $6.9M | $11M |
| −$7.4M | −$9.3M | −$15.4M | −$22M | |
| Pre-tax income | −$8.8M | −$8.7M | −$13.8M | −$19.9M |
| $0 | $0 | $0 | $0 | |
| Net income | −$8.8M | −$8.7M | −$13.8M | −$19.9M |
| −$3.96 | −$3.81 | −$0.69 | −$0.59 | |
| 2.2M | 2.3M | 19.9M | 33.4M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest SpyGlass Pharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SGPSpyGlass Pharma | $1.1B | n/m | n/a | n/m | n/m | n/m | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| LMATLemaitre Vascular | $1.9B | 28.5× | 42.0× | 7.1× | +12% | 25.0% | |
| INSPInspire Medical Systems | $1.9B | 14.5× | 56.6× | 2.2× | −0% | 15.0% | |
| UFPTUFP Technologies | $2.2B | 30.6× | 25.6× | 3.5× | +7% | 11.4% | |
| Peer median | $1.3B | 29.6× | 41.7× | 2.1× | +8% | 7.7% |
More on SpyGlass Pharma
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .